Avid Bioservices Inc (CDMO)

[sulaco]

Hut, Novartis could buy PPHM for $12B

without a hiccup. $12B is pocket change to these guys.

$12B would give a pps of $240.

But the plot thickens.

The Big Boys so far who want anti-PD1's badly, and who HATE Merck's Keytruda and BMY's Opdivo:

JNJ
PFE
GILD
RHBBY (Roche)
AZN
ADR (Novartis)

Everyone of them is desperate for an anti-PD1. Now everyone knows that the I/O 2.0 paradigm is COMBO therapy. My question is combo with what?

Not CTLA-4. That's 2 downstreamers and results have been disappointing. 40% responders and very limiting autoimmune side effects: diabetes, lupus, pneumonitis, Crohn's colitis, etc.

Of course, do not forget Opdivo's serious stumble in August, 2016 with its NSCLC trial showing NO DIFFERENCE with chemotherapy.

MRK's stock jumped with that news, due to Keytruda.

So what's needed? Ask Wolchok. Jed wanted PS Blockade PRECISELY because he knows downstreamers can't do it alone.

Too many non-responders. Too many relapses (which the omnipresent commercials don't mention). Everytime I see an Opdivo commercial (you know, the one with the tall Opdivo Building), or a Keytruda ad (you know, the lung cancer woman survivor doing an interview, with makeup), I just have to smile.

Because I know what's needed. It's PS Blockade. Upstream conditioning so the downstreamers can contribute without the devastating side effects.

COMBO therapy. The future. AIMO.

Best,

Joe Six Pack